Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a research report released on Wednesday morning.

Several other research firms also recently weighed in on ABUS. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $5.00 price target (up previously from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. Finally, JMP Securities increased their price target on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Performance

ABUS stock opened at $3.46 on Wednesday. The company has a market capitalization of $655.64 million, a price-to-earnings ratio of -8.05 and a beta of 1.93. Arbutus Biopharma has a fifty-two week low of $2.30 and a fifty-two week high of $4.73. The stock has a fifty day moving average of $3.33 and a 200-day moving average of $3.65.

Institutional Trading of Arbutus Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. E Fund Management Co. Ltd. purchased a new stake in Arbutus Biopharma during the 4th quarter worth about $34,000. Xponance Inc. purchased a new stake in Arbutus Biopharma during the 4th quarter worth about $34,000. Raymond James Financial Inc. purchased a new stake in Arbutus Biopharma during the 4th quarter worth about $34,000. Cibc World Markets Corp purchased a new stake in Arbutus Biopharma during the 4th quarter worth about $45,000. Finally, Hsbc Holdings PLC purchased a new stake in Arbutus Biopharma during the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.